Drug Trial Radar · NCT03277105
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
522
Actual
Start
Oct 27, 2017
Primary completion
Jun 27, 2019
Study completion Jan 12, 2024
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).
Conditions
- Multiple Myeloma
Interventions
Dara SCDrug
Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Dara IVDrug
Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 1 year 8 months
- Maximum Trough Concentration (Ctrough) of DaratumumabTime frame: Predose on Cycle 3 Day 1 (each cycle of 28 days)
Locations
146 sites in 18 countries. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts
Levine Cancer Institute
Charlotte, North Carolina
Royal Prince Alfred Hospital
Camperdown, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Alfred Health
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
The Queen Elizabeth Hospital
Woodville South, Australia
Princess Alexandra Hospital
Woolloongabba, Australia
Fundacao Pio XII
Barretos, Brazil
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
Florianópolis, Brazil
Fundacao Doutor Amaral Carvalho
Jaú, Brazil
Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
Joinville, Brazil
Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo
Passo Fundo, Brazil
Hospital das Clinicas de Porto Alegre
Porto Alegre, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude
Rio de Janeiro, Brazil
CEHON
Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
São José do Rio Preto, Brazil
Clinica Sao Germano
São Paulo, Brazil
Hospital Das Clinicas Da Faculdade De Medicina Da USP
São Paulo, Brazil
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
The Gordon & Leslie Diamond Health Care Center
Vancouver, British Columbia, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Victoria Hospital
London, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
CHU de Quebec L Hotel Dieu de Quebec
Québec, Quebec, Canada
Fakultni nemocnice Brno
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni Nemocnice Ostrava
Ostrava, Czechia
Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni
Pilsen, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
Prague, Czechia
CHU Caen - Côte de Nacre
Caen, France
Hopital Claude Huriez
Lille, France
CHU de Nantes hotel Dieu
Nantes, France
CHU de Boreaux
Pessac, France
Centre hospitalier Lyon-Sud
Pierre-Bénite, France
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.